Adani Enterp.

3000down-arrow-19.30

Adani Ports

1280down-arrow-15.55

Apollo Hospitals

6140down-arrow65.85

Asian Paints

2790down-arrow-17.70

Axis Bank

1015down-arrow-9.00

B P C L

578down-arrow-11.60

Bajaj Auto

9075.05down-arrow53.75

Bajaj Finance

6840.05down-arrow-53.15

Bajaj Finserv

1587down-arrow-6.90

Bharti Airtel

1280down-arrow14.25

Britannia Inds.

4682.05down-arrow-12.95

Cipla

1347down-arrow-0.30

Coal India

436down-arrow-2.60

Divi's Lab.

3661down-arrow-47.90

Dr Reddy's Labs

6000down-arrow42.85

Eicher Motors

4345down-arrow-6.20

Grasim Inds

2220down-arrow-6.05

HCL Technologies

1442down-arrow-24.85

HDFC Bank

1486.55down-arrow-8.15

HDFC Life Insur.

600down-arrow-5.65

Hero Motocorp

4251.25down-arrow-0.05

Hind. Unilever

2220down-arrow5.20

Hindalco Inds.

609down-arrow-3.80

ICICI Bank

1052.95down-arrow-2.50

IndusInd Bank

1466down-arrow-8.40

Infosys

1385down-arrow-34.25

ITC

418down-arrow-0.85

JSW Steel

842.85down-arrow-1.95

Kotak Mah. Bank

1764down-arrow-22.75

Larsen & Toubro

3525down-arrow-25.95

LTIMindtree

4650down-arrow-47.15

M & M

2034down-arrow9.05

Maruti Suzuki

12399.9down-arrow-5.10

Nestle India

2430down-arrow-32.55

NTPC

343.1down-arrow-8.05

O N G C

276.75down-arrow2.60

Power Grid Corpn

278.1down-arrow-2.00

Reliance Industr

2913.55down-arrow-15.10

SBI Life Insuran

1450down-arrow-6.95

Shriram Finance

2349.85down-arrow-21.60

St Bk of India

734.5down-arrow-10.30

Sun Pharma.Inds.

1505down-arrow-11.40

Tata Consumer

1104.5down-arrow-30.05

Tata Motors

964down-arrow-7.35

Tata Steel

160down-arrow-0.05

TCS

3838down-arrow-24.00

Tech Mahindra

1163.05down-arrow-16.60

Titan Company

3525.1down-arrow0.00

UltraTech Cem.

9325down-arrow-57.75

Wipro

440down-arrow-4.35

Corporate News - Detailed News Back
Natco Pharma receives USFDA approval for Carfilzomib Vials ANDA
14-Jun-21   12:56 Hrs IST
Natco Pharma has received approval for its Abbreviated New Drug Application (ANDA) for Carfilzomib Vials ANDA (generic for KYPROLIS®), from the U.S. Food and Drug Administration (USFDA).

The parties have received final approval for 10mg and 60mg strengths of the product and tentative approval for 30mg strength of the product. Based on the ANDA filing date NATCO believes that it is eligible for 180 days of sole generic marketing exclusivity for the 10mg strength and shared 180 days of generic marketing exclusivity for the 60mg strength of the product at the time of launch.

Powered by Capital Market - Live News


NASDAQ 15601.50
-81.87 -0.52%
DJIA 37775.38
22.07 0.06%
S&P 500 5011.12
-11.09 -0.22%
HANG SENG 16385.87
134.03 0.82%
NIKKEI 225 38079.70
117.90 0.31%
STRAITS TIMES 3187.66
32.97 1.05%
FTSE 100 7877.05
29.06 0.37%
KLSE COMPOSITE 1544.76
4.34 0.28%
JAKARTA COMPOSITE 7166.81
35.97 0.50%
NIFTY 21861.50
-134.35 -0.61%
×
Ask Your Question
close
refresh